ReviewNature reviews. Endocrinology2012
Management of diabetes mellitus: is the pump mightier than the pen?
Review in Nature reviews. Endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.
- The evidence base for diabetes technology: appropriate and inappropriate meta-analysis.Journal of diabetes science and technology · 2013Pooled it
- A Pilot Study of Flat and Circadian Insulin Infusion Rates in Continuous Subcutaneous Insulin Infusion (CSII) in Adults with Type 1 Diabetes (FIRST1D).Journal of diabetes science and technology · 2021Trial
- A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).Diabetes, obesity & metabolism · 2019Trial
- Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels.Clinical endocrinology · 2016Trial
- Accuracy of a new patch pump based on a microelectromechanical system (MEMS) compared to other commercially available insulin pumps: results of the first in vitro and in vivo studies.Journal of diabetes science and technology · 2014Trial
- Continuous Intraperitoneal Insulin Infusion for People With Type 1 Diabetes: A Literature Review and International Position Statement.Diabetes, obesity & metabolism · 2026Review
- Efficacy of Novel Drug Delivery Systems for Insulin Administration and Technological Advances in Diabetes Mellitus: Review.AAPS PharmSciTech · 2025Review
- MDI versus CSII in Chinese adults with type 1 diabetes in a real-world situation: based on propensity score matching method.Health and quality of life outcomes · 2024Article
- Biomedical applications of stimuli-responsive "smart" interpenetrating polymer network hydrogels.Materials today. Bio · 2024Review
- In Silico Investigation of the Clinical Translatability of Competitive Clearance Glucose-Responsive Insulins.ACS pharmacology & translational science · 2023Article
- Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study.Diabetologia · 2023Article
- Improvements in Glycemic Outcomes in 4738 Children, Adolescents, and Adults with Type 1 Diabetes Initiating a Tubeless Insulin Management System.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Machine Learning-Based Anomaly Detection Algorithms to Alert Patients Using Sensor Augmented Pump of Infusion Site Failures.Journal of diabetes science and technology · 2022Article
- Function and Emotion in Everyday Life With Type 1 Diabetes (FEEL-T1D): Protocol for a Fully Remote Intensive Longitudinal Study.JMIR research protocols · 2021Article
- A Fully Integrated Closed-Loop System Based on Mesoporous Microneedles-Iontophoresis for Diabetes Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Article
- An Insulin Bolus Advisor for Type 1 Diabetes Using Deep Reinforcement Learning.Sensors (Basel, Switzerland) · 2020Article
- Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin.Diabetes · 2020Article
- Insulin-delivery methods for children and adolescents with type 1 diabetes.Therapeutic advances in endocrinology and metabolism · 2020Review
- Long-Term Effects of Initiating Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring (CGM) in People with Type 1 Diabetes and Unsatisfactory Diabetes Control.Journal of clinical medicine · 2019Article
- The process of incorporating insulin pumps into the everyday lives of people with Type 1 diabetes: A critical interpretive synthesis.Health expectations : an international journal of public participation in health care and health policy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Continuous subcutaneous insulin infusion (CSII, or insulin pump therapy) reduces HbA1c levels and hypoglycaemia in patients with type 1 diabetes mellitus (T1DM) compared with multiple daily insulin injections (MDI). The greatest reduction in HbA(1c) levels with CSII occurs in patients with the worst glycaemic control; therefore, the most appropriate and cost-effective use of CSII in adults with T1DM is in those who have continued, elevated HbA(1c) levels or disabling hypoglycaemic episodes with MDI (including the use of long-acting insulin analogues and structured patient education). The disadvantages of CSII include higher costs than MDI and the risk of ketosis in the event of pump failure. In children with T1DM, CSII may be used when MDI is considered impractical or inappropriate. Pumps are not generally recommended for patients with type 2 diabetes mellitus but may improve control in some subgroups. A new generation of smaller insulin infusion pumps with an integrated cannula, called patch pumps, could improve uptake of CSII in general. The important clinical question is not whether CSII is more efficacious than MDI in general adult T1DM, but whether CSII further improves glycaemic control when this control continues to be poor with MDI, and evidence exists that in most cases it does.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.